Cardiac PET Myocardial Perfusion Imaging (MPI) is a Medicare approved first line test for non-invasive cardiology evaluation that is projected to grow over 60% in the next 5 years.1

Cardiac PET is rapidly being adopted and it’s not a matter of if cardiac PET is coming, it is a matter of when. It is a powerful, non-invasive imaging tool available now that can assess myocardial blood flow (MBF) of the entire coronary circulation and has been demonstrated to be useful in the assessment of microvascular and triple vessel disease. Microvascular disease is known to be highly prevalent in women, as well as patients with cardiometabolic risk factors.2

2. DiCarli MF 2021: doi:10.2967/jnumed.120.254979
Cardiac Imaging Outpatient Services 5 Year National Growth Estimate
Cardiac CT 12%
Cardiac MRI 17.6%
Myocardial PET 64.9%
Electrocardiogram 7.9 %
Transthoracic ECHO 16.4%
Stress Test 4.5%

Advisory Board 2019


Compact Cyclotron Technology

The backbone of the IONETIX N-13 Ammonia solution is a superconducting compact cyclotron. Featuring a patent-protected design based on superconducting magnets, the ION-12SC compact cyclotron has a substantially smaller footprint than traditional cyclotrons making installation on or near medical campuses more attainable than ever before. The compact cyclotron ensures a consistent and reliable radiopharmaceutical at the point-of-care and provides you with complete control of patient testing schedules.

Download the Fact Sheet
Compact Cyclotron
Targeted Alpha Therapy

Coming soon…

We are in the process of equipping a new Targeted Alpha Therapy Manufacturing Center, for full cGMP drug manufacturing capabilities including a 30 MeV cyclotron unit for alpha radionuclide production to support pre-clinical research, drug development, and early stage clinical trials. Read the press release

Learn more about alpha therapy

Ready to elevate your Cardiac PET imaging program?

The time is now to consider a complete end-to-end cyclotron solution.

Contact us